中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (9): 589-593.doi: 10.12144/zgmfskin202209589

• 论著 • 上一篇    下一篇

系统性硬化症163例临床分析

蔡金云1,2,傅萍1,孙瑞希1,寸杏珠1,熊瑞芳1   

  1. 1昆明医科大学第二附属医院风湿免疫科，昆明，650101;2现工作单位：攀枝花市中心医院风湿免疫科，攀枝花，617000
  • 出版日期:2022-09-15 发布日期:2022-07-13

Analysis of 163 patients with systemic sclerosis

CAI Jinyun1，2, FU Ping1, SUN Ruixi1, CUN Xingzhu1, XIONG Ruifang1   

  1. 1 Department of Rheumatology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China;2 Department of Rheumatology, Panzhihua Central Hospital, Panzhihua 617000, China
  • Online:2022-09-15 Published:2022-07-13

PDF (PC)

240

摘要： 回顾性分析163例系统性硬化症（SSc）患者的临床资料，分析其类型、临床表现、实验室检查及治疗的特点，增加对该罕见病的认识。结果示本组病例中dcSSc 95 例，lcSSc 49 例，重叠综合征14 例，UCTD 4 例和sine scleroderma 1例。皮肤表现包括肿胀（18例）， 硬化（106例），萎缩（11例）。SSc患者163例平均mRSS评分12.0。全身各器官系统均有不同程度受累，雷诺现象最多见（51.0%）。多因素logistic回归分析示球蛋白升高是SSc累及血液系统的独立危险因素。150例患者使用糖皮质激素联合抗风湿药(DMARDs)治疗，13例使用糖皮质激素联合DMARDs及托珠单抗治疗，有一定疗效。

关键词: 系统性硬化, 血液, 托珠单抗, 危险因素

Abstract:

The data of 163 patients with systemic sclerosis (SSc) were analyzed retrospectively, including subtype, clinical manifestation and treatment. Of 163 patients, 95 were dcSSc, 49 were lcSSc, 14 were overlap syndrome, 4 were UCTD, 1 was sine scleroderma. The dermatologic manifestations included swelling (18 cases), hardening (106 cases), atrophy (11 cases). The average score of mRSS (the modified Rodnan skin score) was 12.0. Many organ systems were affected and Raynaud phenomenon (51.0%) was the most common. Multivariate logistic regression showed  the high level of globulin was an independent risk factor of SSc involved hematologic system. 150 patients were treated with glucocorticoid combined with disease-modifying antirheumatic drugs (DMARDs) and 13 patients were treated with glucocorticoid combined with DMARDs and tocilizumab and those method showed some efficacy.

［Key words］systemic sclerosis; blood; tocilizumab; risk factor

Key words: systemic sclerosis, blood, tocilizumab, risk factor